You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameReserpine
Accession NumberDB00206  (APRD00472)
TypeSmall Molecule
GroupsApproved
Description

An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. [PubChem]

Structure
Thumb
Synonyms
(-)-Reserpine
(−)-reserpine
(3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester
3,4,5-trimethoxybenzoyl methyl reserpate
Apoplon
Reserpin
Reserpine
Serpalan
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-reserpine Tab 0.25mgtablet.25 mgoralNovopharm Limited1967-12-312005-08-10Canada
Reserpinetablet.1 mg/1oralEon Labs, Inc.1988-03-11Not applicableUs
Reserpinetablet.25 mg/1oralEon Labs, Inc.1988-03-11Not applicableUs
Serpasil 0.25mgtablet0.25 mgoralNovartis Pharmaceuticals Canada Inc1954-12-311999-08-04Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ApoplonNot Available
HiserpiaNot Available
NovoreserpineNot Available
ReserfiaNot Available
SerpalanNot Available
SerpanrayNot Available
SerpasilNot Available
Brand mixtures
NameLabellerIngredients
Hydropres 25 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Hydropres 50 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Ser-AP-ES TabNovartis Pharmaceuticals Canada Inc
SaltsNot Available
Categories
UNII8B1QWR724A
CAS number50-55-5
WeightAverage: 608.6787
Monoisotopic: 608.273380888
Chemical FormulaC33H40N2O9
InChI KeyInChIKey=QEVHRUUCFGRFIF-MDEJGZGSSA-N
InChI
InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1
IUPAC Name
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyloxy)-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
SMILES
[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[[email protected]](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as yohimbine alkaloids. These are alkaloids containing the pentacyclic yohimban skeleton. The Yohimbinoid alkaloids contain a carbocyclic ring E arising through C-17 to C-18 bond formation in a corynantheine precursor.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassYohimbine alkaloids
Sub ClassNot Available
Direct ParentYohimbine alkaloids
Alternative Parents
Substituents
  • Yohimbine
  • Corynanthean skeleton
  • Yohimbine alkaloid
  • Pyridoindole
  • Beta-carboline
  • Gallic acid or derivatives
  • P-methoxybenzoic acid or derivatives
  • M-methoxybenzoic acid or derivatives
  • Benzoate ester
  • Indole or derivatives
  • Indole
  • Benzylether
  • Benzoic acid or derivatives
  • Methoxybenzene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Methyl ester
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFoe the treatment of hypertension
PharmacodynamicsReserpine is an adrenergic blocking agent used to treat mild to moderate hypertension via the disruption of norepinephrine vesicular storage. The antihypertensive actions of Reserpine are a result of its ability to deplete catecholamines from peripheral sympathetic nerve endings. These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral resistance.
Mechanism of actionReserpine's mechanism of action is through inhibition of the ATP/Mg2+ pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding62%
MetabolismNot Available
Route of eliminationReserpine is extensively metabolized to inactive compounds. It is slowly excreted via the urine and feces.
Half lifeNot Available
ClearanceNot Available
ToxicityPossible human carcinogen. May cause reproductive harm. ORL-RAT LD50 420 mg/kg; IPR-RAT LD50 44 mg/kg; IVN-RAT LD50 15 mg/kg; ORL-MUS LD50 200 mg/kg; SCU-MUS LD50 52 mg/kg; IPR-RBT LD50 7 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9216
Blood Brain Barrier+0.9257
Caco-2 permeable+0.6549
P-glycoprotein substrateSubstrate0.7928
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.75
Renal organic cation transporterInhibitor0.5194
CYP450 2C9 substrateNon-substrate0.8859
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7065
CYP450 1A2 substrateInhibitor0.8965
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9384
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7062
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9439
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1297 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7505
hERG inhibition (predictor II)Non-inhibitor0.6194
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Eli lilly and co
  • Bowman pharmaceuticals inc
  • Bristol myers squibb co
  • Barr laboratories inc
  • Bell pharmacal corp
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • Halsey drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Marshall pharmacal corp
  • Mk laboratories inc
  • Mylan pharmaceuticals inc
  • Pharmavite pharmaceuticals
  • Purepac pharmaceutical co
  • Private formulations inc
  • Rexall drug co
  • Roxane laboratories inc
  • Sandoz inc
  • Solvay pharmaceuticals
  • Tablicaps inc
  • Teva pharmaceuticals usa inc
  • Valeant pharmaceuticals international
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Lannett co inc
  • Panray corp sub ormont drug and chemical co inc
  • Vale chemical co inc
  • Vitarine pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral.25 mg
Tabletoral.1 mg/1
Tabletoral.25 mg/1
Tabletoral
Tabletoral0.25 mg
Prices
Unit descriptionCostUnit
Reserpine 0.25 mg tablet1.52USD tablet
Reserpine 0.1 mg tablet0.83USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point264.5 °CPhysProp
water solubility73 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.2Not Available
pKa6.6MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0113 mg/mLALOGPS
logP4.05ALOGPS
logP3.53ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)16.29ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area117.78 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity161.42 m3·mol-1ChemAxon
Polarizability66.05 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.3 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-2943000000-8f7998aa667566277f3fView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Authors unspecified: Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979 Dec 7;242(23):2562-71. [PubMed:490882 ]
  2. Authors unspecified: Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967 Dec 11;202(11):1028-34. [PubMed:4862069 ]
  3. Authors unspecified: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991 Jun 26;265(24):3255-64. [PubMed:2046107 ]
  4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. Epub 2003 May 14. [PubMed:12748199 ]
  5. Moser M: "Cost containment" in the management of hypertension. Ann Intern Med. 1987 Jul;107(1):107-9. [PubMed:3592424 ]
External Links
ATC CodesC02LA51C02AA52C02LA01C02LA71C02AA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
AcebutololReserpine may increase the hypotensive activities of Acebutolol.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Reserpine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Reserpine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Reserpine.
AmifostineReserpine may increase the hypotensive activities of Amifostine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Reserpine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Reserpine.
AmphetamineReserpine may decrease the stimulatory activities of Amphetamine.
AtenololReserpine may increase the hypotensive activities of Atenolol.
AzelastineReserpine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Reserpine.
BenzphetamineReserpine may decrease the stimulatory activities of Benzphetamine.
BetaxololReserpine may increase the hypotensive activities of Betaxolol.
BisoprololReserpine may increase the hypotensive activities of Bisoprolol.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Reserpine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Reserpine.
BrimonidineBrimonidine may increase the antihypertensive activities of Reserpine.
BuprenorphineReserpine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Reserpine.
ButabarbitalButabarbital may increase the hypotensive activities of Reserpine.
ButethalButethal may increase the hypotensive activities of Reserpine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Reserpine.
CarteololReserpine may increase the hypotensive activities of Carteolol.
CarvedilolReserpine may increase the hypotensive activities of Carvedilol.
CathinoneThe serum concentration of Cathinone can be decreased when it is combined with Reserpine.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Reserpine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Reserpine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Reserpine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Reserpine.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reserpine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Reserpine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Reserpine.
DextroamphetamineReserpine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Reserpine.
DiazoxideDiazoxide may increase the hypotensive activities of Reserpine.
DigoxinThe risk or severity of adverse effects can be increased when Reserpine is combined with Digoxin.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Reserpine.
DonepezilDonepezil may increase the central neurotoxic activities of Reserpine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Reserpine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Reserpine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
DuloxetineReserpine may increase the orthostatic hypotensive activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Reserpine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Reserpine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Reserpine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Reserpine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Reserpine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Reserpine.
EsmololReserpine may increase the hypotensive activities of Esmolol.
EthanolReserpine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Reserpine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Reserpine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Reserpine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Reserpine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Reserpine.
GalantamineGalantamine may increase the central neurotoxic activities of Reserpine.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Reserpine.
HexobarbitalHexobarbital may increase the hypotensive activities of Reserpine.
HydrocodoneReserpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Reserpine.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Reserpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Reserpine.
LabetalolReserpine may increase the hypotensive activities of Labetalol.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Reserpine.
LevobunololReserpine may increase the hypotensive activities of Levobunolol.
LevodopaReserpine may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Reserpine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Reserpine.
LisdexamfetamineReserpine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Reserpine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Reserpine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Reserpine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Reserpine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Reserpine.
MethamphetamineReserpine may decrease the stimulatory activities of Methamphetamine.
MethohexitalMethohexital may increase the hypotensive activities of Reserpine.
MethotrimeprazineReserpine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Reserpine.
MetipranololReserpine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Reserpine.
MetoprololReserpine may increase the hypotensive activities of Metoprolol.
MetyrosineReserpine may increase the sedative activities of Metyrosine.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Reserpine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
MirtazapineReserpine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Reserpine.
MolsidomineMolsidomine may increase the hypotensive activities of Reserpine.
MoxonidineMoxonidine may increase the hypotensive activities of Reserpine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
NadololReserpine may increase the hypotensive activities of Nadolol.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Reserpine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Reserpine.
NebivololReserpine may increase the hypotensive activities of Nebivolol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Reserpine.
NicorandilNicorandil may increase the hypotensive activities of Reserpine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Reserpine.
ObinutuzumabReserpine may increase the hypotensive activities of Obinutuzumab.
OrphenadrineReserpine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParaldehydeReserpine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Reserpine.
PenbutololReserpine may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Reserpine.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Reserpine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Reserpine.
PhendimetrazineReserpine may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Reserpine.
PhentermineReserpine may decrease the stimulatory activities of Phentermine.
PindololReserpine may increase the hypotensive activities of Pindolol.
PramipexoleReserpine may increase the sedative activities of Pramipexole.
PrimidonePrimidone may increase the hypotensive activities of Reserpine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Reserpine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Reserpine.
PropranololReserpine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Reserpine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Reserpine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Reserpine.
QuinidineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Reserpine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Reserpine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Reserpine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Reserpine.
RisperidoneReserpine may increase the hypotensive activities of Risperidone.
RituximabReserpine may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the central neurotoxic activities of Reserpine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Reserpine.
RopiniroleReserpine may increase the sedative activities of Ropinirole.
RotigotineReserpine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Reserpine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Reserpine.
SecobarbitalSecobarbital may increase the hypotensive activities of Reserpine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Reserpine.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Reserpine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Reserpine.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
SotalolReserpine may increase the hypotensive activities of Sotalol.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Reserpine.
SuvorexantReserpine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TadalafilTadalafil may increase the antihypertensive activities of Reserpine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Reserpine.
TetrabenazineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrabenazine.
ThalidomideReserpine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TimololReserpine may increase the hypotensive activities of Timolol.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Reserpine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Reserpine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reserpine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Reserpine.
TreprostinilTreprostinil may increase the hypotensive activities of Reserpine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Reserpine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Reserpine.
VardenafilVardenafil may increase the antihypertensive activities of Reserpine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Reserpine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Reserpine.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Reserpine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Reserpine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Reserpine.
YohimbineYohimbine may decrease the antihypertensive activities of Reserpine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Reserpine.
ZolpidemReserpine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Magnesium, potassium and zinc needs increased.
  • Take with food to reduce irritation. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sievert MK, Hajipour AR, Ruoho AE: Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels. Anal Biochem. 2007 Aug 1;367(1):68-78. Epub 2007 May 3. [PubMed:17559790 ]
  4. Naudon L, Leroux-Nicollet I, Raisman-Vozari R, Botton D, Costentin J: Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex. Synapse. 1995 Sep;21(1):29-36. [PubMed:8525459 ]
  5. Erickson JD, Eiden LE, Hoffman BJ: Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10993-7. [PubMed:1438304 ]
  6. Mandela P, Chandley M, Xu YY, Zhu MY, Ordway GA: Reserpine-induced reduction in norepinephrine transporter function requires catecholamine storage vesicles. Neurochem Int. 2010 May-Jun;56(6-7):760-7. doi: 10.1016/j.neuint.2010.02.011. Epub 2010 Feb 20. [PubMed:20176067 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin transmembrane transporter activity
Specific Function:
Involved in the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles of neuroendocrine and endocrine cells.
Gene Name:
SLC18A1
Uniprot ID:
P54219
Molecular Weight:
56256.71 Da
References
  1. Ashe KM, Chiu WL, Khalifa AM, Nicolas AN, Brown BL, De Martino RR, Alexander CP, Waggener CT, Fischer-Stenger K, Stewart JK: Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain. Neuro Endocrinol Lett. 2011;32(3):253-8. [PubMed:21712771 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  4. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  5. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  6. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153 ]
  7. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  8. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  9. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994 Dec 8;372(6506):549-52. [PubMed:7990927 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
  2. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schomig E: Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998 Nov 20;273(47):30915-20. [PubMed:9812985 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23